History

- 2020
  - Remimazolam : Execution of the extended license agreement for 6 major SE Asian countries between Hana Pharm and Paion AG, Germany in January
- 2019
  - Remimazolam : Submission of NDA accepted by MFDS, Korea in December
  - Initiated P1 of MRI contrast agent
  - Investment of Injectable Plant, EU & J GMP facility for exports abroad (KRW 58.5bn)
  - Investment of new site to Pyeongtaek Dream Tech industrial complex (KRW 29.8bn)
- 2018
  - Remimazolam : P3 study completed in October
  - Selection and implementation of governmental tasks on the development of novel drug having VEGF(R) inhibitory properties for diabetic retinopathy. (Ministry of Health & Welfare)
  - Selection and implementation of governmental tasks on biolipid's interactomics research center. (Ministry of Science and ICT)
- 2017
  - Release of anti-emetic Paloxi Inj. (Palonosetron)
  - 2017 sales of 139.3 billion won (11% growth from the previous year)
  - Release of narcotic analgesics Ocodone Inj. (Oxycodone)
  - Development of new MRI contrast media “Gd-proton project (HNP-2006)”
- 2016
  - 2016 sales of 125.2 billion won (16% growth from the previous year)
  - Finished product warehouse / DPS room expansion
  - Opening of Pangyo R&D Center
- 2015
  - 2015 sales of 108.3 billion won (22% growth from the previous year)
    Prefilled Syringe
  - Expansion of prefilled syringe production line
- 2014
  - 2014 sales of 89 billion won (9% growth from the previous year)
  - Release of narcotic analgesic Remiva Inj. (Remifentanil)
- 2013
  - 2013 sales of 81.6 billion won (11% growth from the previous year)
  - New drug Remimazolam partnership with Paion of Germany
  - Expansion of lyophilized injection production line
- 2012
  - 2012 sales of 74.1 billion won
- 2011
  - 2011 sales of 80.5 billion won (2% growth from the previous year)
  - Release of anti-emetic Ramset Inj. (Ramosetron)
- 2010
  - 2010 sales of 79.4 billion won (37% growth from the previous year)
  - Completion of Hagil Central Laboratory
  - Co-promotion of a new drug Precedex Inj. (Dexmedetomidine)
    with Hospira of USA
- 2009
  - 2009 sales of 58.1 billion won (35% growth from the previous year)
  - Release of narcotic analgesics Ocodone CR (Oxycodone)
- 2008
  - 2008 sales of 43 billion won (4% growth from the previous year)
  - Change of Hana Pharm CI
  - Release of inhalation anesthetic (Sevoflurane) and Ifran Liq. (Isoflurane)
- 2007
  - 2007 sales of 41.4 billion won (12% growth from the previous year)
  - Completion of Hagil factory of state-of-the-art facility of EU GMP level
- 2006
  - 2006 sales of 37 billion won (8% growth from the previous year)
  - Domestic release of inhalation anesthetic Terrell (Isoflurane) and Compound347 (Enflurane)
  - Export of Anepol Inj. (Propofol) to Indonesia
  - New establishment of laboratory
- 2005
  - 2005 sales of 34.2 billion won (17% growth from the previous year)
  - Export contract of Anepol Inj.(propofol) and Atra Inj.(Atracurium) to China
  - Supply contract of inhalation anesthetic with MINRAD of USA
- 2004
  - 2004 sales of 29.3 billion won (26% growth from the previous year)
  - Export of Anepol Inj. (Propofol) to Vietnam
  - Expansion of the Central Laboratory
  - Designation as the qualified BGMP company
  - Export of Anepol Inj.(Propofol) to Thailand
  - Export contract of Anepol Inj. (Propofol) and Atra Inj.(Atracurium) to Russia
- 2003
  - Completion of Hyangnam factory (drug substance synthesis factory), expansion of the Central Laboratory
  - Export of Anepol Inj. (Propofol) to Brazil
- 2002
  - Export of Cenital tab. (Aceclofenac) to Vietnam
  - Export contract of Anepol Inj. (Propofol) to Indonesia
  - First domestic release of Fentas Patch (narcotic analgesic patch)
- 2001
  - Export contract of Anepol Inj. (Propofol) to Brazil
- 2000
  - Export of Kepiten tab. (Ketotifen) and Bacylovir cream (Acyclovir)
    to Hong Kong
  - Export of Cafenac SR (Diclofenac) to Pakistan
- 1999
  - Release of Anepol Inj. (Propofol)
  - Completion of the Central Laboratory (attached synthesis room)
- 1998
  - Establishment of the Central Laboratory
- 1997
  - Expansion of Hyangnam Factory
  - Market release of injections (narcotic analgesics, muscle relaxants, etc.)
- 1996
  - Establishment of Hana Pharm
    (Merge with Woocheon Pharmaceutical)
Woocheon Pharmaceutical

1991
Designation as a KGMP qualified company (MFDS)

1988
Completion of KGMP
(Korean Good Manufacturing Practice) factory (solid, capsule)

1978
Transformation of Woocheon Pharmaceutical into a corporation

1958
Establishment of Woocheon Pharmaceutical

History

Woocheon Pharmaceutical